The tweet was deleted by the author.
But we saved everything 🙂.
Lineage Cell Therapeutics has announced its entry into the market for corneal endothelial disease with the introduction of COR1, targeting the growing global population affected by Fuchs endothelial corneal dystrophy (FECD).
The company’s strategy aims to address unmet clinical needs in ophthalmology, leveraging cell therapy innovations to support patients with degenerative eye disorders. FECD is increasingly recognized as a major cause of vision impairment worldwide. The expansion underscores Lineage Cell Therapeutics' intent to broaden its footprint in regenerative medicine and ophthalmic therapeutics.
Lineage Cell Therapeutics recently launched COR1 as a preclinical cell therapy targeting both Fuchs dystrophy and Bullous Keratopathy, supported by its AlloSCOPE technology platform, according to a previous report. CEO Brian Culley has also promoted scalable platforms to manage the complexity of drug discovery in the company's pipeline, as noted in an earlier announcement. These initiatives mark continued efforts to expand in regenerative medicine and ophthalmology.